From Our 2012 Archives
Asthma Drug Shown to Stunt Growth
Latest Asthma News
Children Who Use Inhaled Steroids Are Slightly Shorter as Adults
By Salynn Boyles
Reviewed by Louise Chang, MD
Sept. 4, 2012 -- Children with asthma who take inhaled steroids end up slightly shorter than their peers when they grow up, a government-funded study shows.
Inhaled steroids are known to slow growth in children during the first years of use, but the long-term impact of inhaled steroids on height was unknown until now.
One researcher says the risk for lower growth may be lowered by adjusting the medication's dose.
Inhaled Steroid Users Slightly Shorter
Adults in the study who had been treated with the inhaled steroid budesonide (Pulmicort) as children were, on average, half an inch shorter than those not treated with a steroid.
This height difference was first seen during treatment, and while the effect persisted into adulthood, it did not get worse, the researchers say.
The findings were presented at the European Respiratory Society Annual Congress in Vienna, Austria to coincide with publication in the New England Journal of Medicine.
Greenville, S.C. asthma specialist Neil Kao, MD, who was not involved with the study, says the findings are surprising.
He says the conventional wisdom has been that inhaled steroids do not permanently affect height.
"The thinking has been that these children catch up, but these findings suggest this is not the case," he says.
Study Brings 'Long Awaited Answer'
Gary Gibbons, MD, director of the National Heart, Lung and Blood Institute, says the study provides the long-awaited answer to the question of whether inhaled steroids have a permanent effect on growth.
But he says the small impact on height must be weighed against the proven superiority of inhaled steroids over other asthma treatments in children.
The study included about 1,000 children with mild to moderate asthma. They were divided into three groups. The first was treated with the inhaled steroid budesonide, the second with the non-steroid inhaled drug nedocromil (which is no longer available in the U.S.), and the third with a placebo.
All three groups also used the non-steroid asthma drug albuterol.
After a year to two years of treatment, children in the inhaled steroid group were an average of a half an inch shorter than children in the other two groups.
Height Deficit Persisted into Mid-20s
The average age of the study participants was 24 when the latest follow-up was done.
"We showed that the height deficit persisted but it did not progress," says researcher Anne Fuhlbrigge, MD, of Boston's Brigham and Women's Hospital.
Researcher William Kelly, PharmD, of the University of New Mexico, says it's now clear that some inhaled steroids affect growth more than others, and that treating children with the lowest effective dose can lower risk.
"Parents should ask if their child is taking the appropriate inhaled [steroid] at the appropriate dosage to minimize this risk," he says.
SOURCES: Kelly, W. New England Journal of Medicine, Sept. 6, 2012. William Kelly, PharmD, University of New Mexico, Albuquerque. Anne L. Fuhlbrigge, MD, clinical director, Pulmonary and Critical Care
Division, Brigham and Women's Hospital, Boston, Mass. Neil Kao, MD, allergy and asthma specialist, Greenville, S.C. Gary Gibbons, MD, director, National Heart Lung and Blood Institute. News release, NIH News. News release, Washington University School of Medicine, St. Louis.